2-hydro-4,4,6,6-tetramethyl-1,3,2-dioxaphosphane | 34883-00-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧杂环化合物
• 英文名称: 2-hydro-4,4,6,6-tetramethyl-1,3,2-dioxaphosphane
• 英文别名: 1,1,3,3-Tetramethyltrimethylenhydrogenphosphit；4,4,6,6-tetramethyl-[1,3,2]dioxaphosphinane 2-oxide；4,4,6,6-tetramethyl-[1,3,2]dioxaphosphinan-2-ol；4,4,6,6-Tetramethyl-2-oxido-1,3,2-dioxaphosphinan-2-ium；4,4,6,6-tetramethyl-2-oxido-1,3,2-dioxaphosphinan-2-ium
• CAS: 34883-00-6
• 化学式: C₇H₁₅O₃P
• 分子量: 178.168
• InChiKey: OGZATZOMTKZRFF-UHFFFAOYSA-N

物化性质

• 熔点：
  61 °C(Solv: ethyl ether (60-29-7))
• 沸点：
  203.1±7.0 °C(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  41.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-甲基吡咯啉 、 2-hydro-4,4,6,6-tetramethyl-1,3,2-dioxaphosphane 以 甲苯 为溶剂， 以63%的产率得到2-methyl-2-(4,4,6,6-tetramethyl-2-oxo-1,3,2-dioxaphosphinan-2-yl)pyrrolidine
  参考文献：
  名称：

  具有近中性 pKa 的新型空间拥挤和构象受限的 α-氨基膦酸盐作为高精度 31P NMR pH 探针。盘基网柄菌细胞微妙 pH 梯度测定的应用

  摘要：

  为了发现新的31 P NMR 标记物用于探测生物环境中的细微 pH 变化（<0.2 pH 单位），合成了 15 种新的构象受限或空间位阻的 α-氨基膦酸盐，它们源自二乙基（2-甲基吡咯烷-2-基）膦酸盐，并测试了它们的 pH 值报告和体外细胞毒性。所有化合物均显示出接近中性的 p K a s（范围为 6.28–6.97）、与磷代谢物不重叠的化学位移和光谱灵敏度（即化学位移变化 Δ δ ab介于酸性和碱性形式之间）范围为 9.2-10.7 ppm，比传统的内源性标记物（如无机磷酸盐）大四倍。X 射线晶体学研究与预测性经验关系和从头计算相结合，解决了与质子化胺功能相关的取代基的诱导和立体化学效应。在 p K a s 与二维结构和磷的金字塔化之间建立了令人满意的相关性，表明磷周围的空间拥挤对于调节 Δ δ ab至关重要。最后，命中31 P NMR pH 探针1b带有未取代的 1,3,2-二氧杂磷环烷环，它具有中等亲脂性，对

  DOI：

  10.3390/molecules27144506
• 作为产物：
  描述：

  2,4-dimethyl-2,4-pentanediol 在 四氮唑 、 水 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 生成 2-hydro-4,4,6,6-tetramethyl-1,3,2-dioxaphosphane
  参考文献：
  名称：

  环状亚磷酰胺及其亚磷酸酯的一些性质：亚磷酸酯化、酯交换和水解

  摘要：

  Phosphorylation of diols using sterically bulky cyclic phosphoramidites was performed in a good selectivity. Their phosphite derivatives underwent tetrazole-catalyzed hydrolysis and transesterification. The reaction was shown to proceed via a phosphorane intermediate by MMR analysis.

  DOI：

  10.3987/com-99-s89

文献信息

• [EN] PURINE COMPOUNDS AS PRODRUGS OF A2B ADENOSINE RECEPTOR ANTAGONISTS, THEIR PROCESS AND MEDICINAL APPLICATIONS<br/>[FR] COMPOSÉS PURINE UTILISÉS EN TANT QUE PROMÉDICAMENTS DES ANTAGONISTES DU RÉCEPTEUR A2B DE L'ADÉNOSINE, LEUR PROCÉDÉ DE PRÉPARATION ET LEURS APPLICATIONS MÉDICALES
  申请人：ADVINUS THERAPEUTICS PRIVATE LTD

  公开号：WO2012035548A1

  公开（公告）日：2012-03-22

  The present disclosure relates to purine compounds of formula (I) or formula (II) or its tautomers, polymorphs, stereoisomers, solvates or a pharmaceutically acceptable salts, or pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by thereof as A2B adenosine receptor antagonists. Formulas should be inserted here} The compounds of the present disclosure are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by the mediation of adenosine A2B receptor. Such conditions include, but are not limited to, asthma, chronic obstructive pulmonary disorder, angiogenesis, pulmonary fibrosis, emphysema, allergic diseases, inflammation, reperfusion injury, myocardial ischemia, atherosclerosis, hypertension, congestive heart failure, retinopathy, diabetes mellitus, obesity, inflammatory gastrointestinal tract disorders including inflammatory bowel disease, sickle cell disease, and/or autoimmune diseases. and to their use in treating mammals for various disease states, such as gastrointestinal disorders, immunological disorders, hypersensitivity disorders, neurological disorders, and cardiovascular diseases due to both cellular hyperproliferation and apoptosis, and the like. The present disclosure also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them.

  本公开涉及式(I)或式(II)的嘌呤化合物或其互变异构体、多晶型、立体异构体、溶剂合物或药学上可接受的盐，或含有它们的药物组合物以及治疗由A2B腺苷受体拮抗剂介导的疾病和病症的方法。应在此处插入公式}本公开的化合物在治疗、预防或抑制可能通过腺苷A2B受体介导而有望改善的疾病和疾病中具有用途。这些疾病包括但不限于哮喘、慢性阻塞性肺病、血管生成、肺纤维化、肺气肿、过敏性疾病、炎症、再灌注损伤、心肌缺血、动脉粥样硬化、高血压、充血性心力衰竭、视网膜病变、糖尿病、肥胖、炎症性胃肠道疾病包括炎症性肠病、镰状细胞病和/或自身免疫疾病。以及它们在治疗哺乳动物各种疾病状态，如胃肠道疾病、免疫性疾病、过敏性疾病、神经系统疾病和心血管疾病中的使用，因细胞过度增殖和凋亡等。本公开还涉及制备此类化合物的方法以及含有它们的药物组合物。
• Pyridine derivatives and production thereof
  申请人：NIPPON SHINYAKU COMPANY, LIMITED

  公开号：EP0159040A2

  公开（公告）日：1985-10-23

  1,4-Dihydropyridine-3-carboxylates having the general formula and the pharmacologically acceptable salts thereof are found to exhibit marked coronary vasodilating, hypotensive and other vasodilating actions with very little toxicity, so that they can be widely applied as remedies for circulatory diseases.

  研究发现，具有通式的 1,4-二氢吡啶-3-羧酸盐及其药理学上可接受的盐类具有明显的冠状动脉血管扩张、降血压和其他血管扩张作用，且毒性极低，因此可广泛用作治疗循环系统疾病的药物。
• CyDEPMPOs: A class of stable cyclic DEPMPO derivatives with improved properties as mechanistic markers of stereoselective hydroxyl radical adduct formation in biological systems
  作者：Gaëlle Gosset、Jean-Louis Clément、Marcel Culcasi、Antal Rockenbauer、Sylvia Pietri

  DOI：10.1016/j.bmc.2011.02.040

  日期：2011.4

  The cis/trans diastereoisomeric composition of hydroxyl radical adducts to chiral cyclic nitrones can be used to approach mechanisms of free radical formation in biological systems. Such determination is greatly simplified when both diastereoisomers have ESR spectra with at least two non-overlapping lines. To achieve this prerequisite, a series of DEPMPO-derived spin traps bearing one unsubstituted or alkyl-substituted 2-oxo-1,3,2-dioxaphosphorinane ring were synthesized and their structures were confirmed by X-ray diffraction, H-1, C-13 and P-31 NMR. These CyDEPMPOs nitrones showed variable lipophilicities and LD50 values on murine fibroblasts compatible with a safe use in biological spin trapping. All CyDEPMPOs formed persistent spin adducts with a series of free radicals, including superoxide and hydroxyl (i.e., CyDEPMPOs-OH) and the in vitro half-life times of these two latter were at least as extended as those of parent DEPMPO. Using four methods of CyDEPMPOs-OH formation, the cis-CyDEPMPOs-OH percentage was found significantly varied with substitution on the P-containing ring and, more interestingly, with the generating system. (C) 2011 Elsevier Ltd. All rights reserved.
• WEISS R.; GRIEND L. J. V.; VERKADE J. G., J. ORG. CHEM., 1979, 44, NO 11, 1860-1863
  作者：WEISS R.、 GRIEND L. J. V.、 VERKADE J. G.

  DOI：——

  日期：——
• US5036059A
  申请人：——

  公开号：US5036059A

  公开（公告）日：1991-07-30